References
- National Institutes of Health. NIH Publication No. 94–882, September 1994; updated April 2000
- Sandler R, Everhart J, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterol 2002;122:1500–11
- Frank L, Kleinman L, Ganoczy D, et al. Upper gastrointestinal symptoms in North America: prevalence and relationship to health care utilization and quality of life. Dig Dis Sci 2000;45:809–18
- Sonnenberg A, Everhart JE. The prevalence of self-reported peptic ulcer in the United States. Am J Public Health 1996;86:200–5
- Everhart JE, Byrd-Holt D, Sonnenberg A. Incidence and risk factors for self-reported peptic ulcer disease in the United States. Am J Epidemiol 1998;147:529–36
- Dean BB, Crawley JA, Schmitt CM, et al. The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 2003;17:1309–17
- Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. Am J Gastroenterol 1997;92:614–20
- Levin TR, Schmittdiel JA, Kunz K, Henning JM, Henke CJ, Colby CJ, Selby JV Costs of acid-related disorders to a health maintenance organization. Am J Med 1997;103:520–8
- Henke C, Levin T, Henning J, et al. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health management organization. Am J Gastroenterol 2000;95:788–92
- Agreus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmaco- economics 2002;20:347–55
- Berndt ER, Bir A, Busch SH, Frank RG, Normand SL. The medical treatment of depression, 1991–1996: productive inefficiency, expected outcome variations, and price indexes. J Health Econ 2002;21: 373–96
- Goetzel RZ, Ozminkowski RJ, Meneades L, Stewart M, Schutt DC. Pharmaceuticals-cost or investment? An employer's perspective. J Occup Environ Med 2000;42:338–51
- Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813–8
- Holzer SS, Juday TR, Joelsson B, Crawley JA. Determining the cost of gastroesophageal reflux disease: a decision analytic model. Am J Manag Care 1998;4:1450–60
- Joish VN, Sahai A. Evaluating the role of confounding in pharmacoeconomic studies. Manag Care Interface 2003;16:31–5
- Iezzoni LI. Risk adjustment for measuring health care outcomes, 2nd edn, 1999, Chicago: Health Administration Press
- Stockdale WA, Brixner DI. Comorbidity influence index. Value in Health 2004;7:232
- Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8–27
- U.S. Department of Labor, Bureau of Labor Statistics. Available from: http://data.bls.gov [Accessed 5 August 2003]
- Graham DY, Rakel RE, Fenderick AM, Go MF, Marshall BJ, Peura DA, Scherger JE. Scope and consequences of peptic ulcer disease: How important is asymptomatic Helicobacter pylori infection? Postgrad Med 1999;105: 100–12
- Cohen J. Statistical power analysis for the behavioral sciences, 2nd edn, 1988. Hillsdale: Lawrence Erlbaum Associates
- Goetzel RZ, Guindon AM, Turshen IJ, et al. Health and productivity management - establishing key performance measures, benchmarks and best prices. J Occup Env Med 2001;43:10–7
- Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903–12
- Sonnenberg A, Schwartz JS, Cutler AF, et al. Cost savings in duodenal ulcer therapy through H. pylori eradication compared with conventional therapies: results of a randomized, doubleblind, multicenter trial. Gastrointerstinal utilization Trial Study Group. Arch Intern Med 1998;158: 852–60